This paper reviews the clinical post-operative manage ment of keratoplasty and the management of corneal graft rejection. In both instances corticosteroids remain the mainstay of treatment; however, the literature shows a wide range for both route and frequency of administration. Grafts at 'high risk ' 
PROPHYLACTIC IMMUNOSUPPRESSION
Virtually all corneal grafts receive immunosuppres sive treatment post-operatively; in the vast majority this includes topical corticosteroid drops, which for many grafts is the only form of treatment given. The usual topical preparations used are 1 % prednisolone and 0.1 % dexamethasone, although weaker prepara tions such as 0.25% or 0.1 % fluorometholone are also used, especially when the side-effects of topical corticosteroids need to be �voided. In a survey of Castroviego Cornea Society members, 4 there was some agreement amongst respondents concerning the choice of preparation used post-operatively in corneal grafting, with 55-68% of respondents preferring 1 % prednisolone acetate and a further 6-8 preferring 1 % prednisolone without specifying the type. Although there was a certain degree of unanimity concerning the preparations used, there was a wide variation in the frequency of usage. In an avascular cornea undergoing a graft for the first time,
100% of respondents used topical steroids post operatively; however, the frequency ranged from twice daily dexamethasone ointment to hourly 1 % prednisolone acetate drops (including night-time!).
The average frequency was four times daily, with 43 % of respondents also using subconjunctival steroids and 7% systemic steroids. In high-risk corneas the frequency range was the same, but the average frequency increased to seven times daily and The presence of a previously rejected graft has also been used as the sole criterion for defining high risk.
However, it has been suggested that a previous graft failure from rejection is not itself a risk factor, 1 8 , 1 9
but that the higher incidence of rejection results from the vascularisation occurring in the rejection process.
In a paper 2 0 reviewing the effect of some of the pre operative risk factors on graft survival, we have also shown that a previously rejected graft is not itself a risk factor. In avascular corneas, survival of a repeat graft was not significantly different from first-time grafts; but in vascular corneas repeat grafts did have a significantly worse survival. This would indicate that in avascular corneas, a history of a previously rejected graft should not be used as the sole criterion for defining high risk. In the same paper we showed that, using multivariate analysis, the only significant risk factor was the number of vascularised quadrants
and not the total number of stromal vessels.
Statistically there was a natural grouping of patients into the following groups: avascular corneas, corneas with 1 or 2 quadrants of vascularisation and corneas with 3+ quadrants of vascularisation. These can be termed low-, medium-and high-risk corneas respec tively. It has been suggested that the vascularisation associated with the rejection line acts as a route for the afferent and efferent arcs of the rejection process.
In the diffuse type it is suggested that the immunological route is via the anterior chamber.
Thus differing routes of immunological contact may be responsible for the differences seen clinically. 6
The reported incidence of endothelial rejection 
